Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 7, 2026, 6:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 55 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Armodafinil Clear all
Completed Phase 2Phase 3 Interventional

Use of Armodafinil for Fatigue in Sarcoidosis

NCT00555347
View directory record Official record
Conditions
Sarcoidosis, Fatigue, Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

Return to Work Randomized Controlled Trial: Counseling After Fatigue Treatment in HIV/AIDS

NCT02140775
View directory record Official record
Conditions
HIV Infection, Fatigue
Interventions
Behavioral Activation Counseling
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Jun 7, 2026, 6:14 AM EDT
Terminated Not applicable Interventional Results available

Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients

NCT01169753
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Placebo, Armodafinil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Effects of Armodafinil on Cognition for Patients With Schizophrenia or Schizoaffective Disorder

NCT00373672
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
armodafinil (Nuvigil), placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal Cancer

NCT01746043
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Armodafinil, Placebo, Minocycline, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Not applicable Interventional Results available

A Study for Reducing Symptom Burden Produced by Chemoradiation Treatment for Non Small Cell Lung Cancer by Minocycline and Armodafinil

NCT01317550
View directory record Official record
Conditions
Lung Cancer
Interventions
Armodafinil, Placebo, Minocycline, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Management of Insomnia in Breast Cancer Patients

NCT01011218
View directory record Official record
Conditions
Insomnia, Fatigue
Interventions
BBT-I, Control, Armodafinil
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2018 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil Treatment (150 mg/Day) as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01305408
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT00481195
View directory record Official record
Conditions
Bipolar I Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
42
States / cities
Birmingham, Alabama • Escondido, California • Lafayette, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Single Agent Armodafinil for Patient-Reported Fatigue Following Radiation Therapy for Head and Neck Cancer

NCT01330446
View directory record Official record
Conditions
Head And Neck Cancer, Fatigue
Interventions
Armodafinil, Placebo, Questionnaires
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

PET Study Examining the Dopaminergic Activity of Armodafinil in Adults

NCT00592943
View directory record Official record
Conditions
Healthy
Interventions
armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Nuvigil on Fatigue

NCT01460628
View directory record Official record
Conditions
Menopause
Interventions
Armodafinil
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 4 Interventional

Behavioral Activation/Armodafinil to Treat Fatigue in HIV/AIDS

NCT01158443
View directory record Official record
Conditions
Hiv, Fatigue, Goals
Interventions
Behavioral Activation Therapy, Supportive Counseling
Behavioral
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2016 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia Fatigue

NCT00678691
View directory record Official record
Conditions
Fibromyalgia, Primary
Interventions
armodafinil, placebo
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia

NCT00772005
View directory record Official record
Conditions
Schizophrenia
Interventions
armodafinil, placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
39
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2012 · Synced Jun 7, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00983437
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil
Drug
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
61
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy

NCT01624480
View directory record Official record
Conditions
Narcolepsy
Interventions
Armodafinil
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jun 7, 2026, 6:14 AM EDT
Terminated Phase 4 Interventional Results available

Armodafinil for Patients Starting Hepatitis C Virus Treatment

NCT01470651
View directory record Official record
Conditions
Hepatitis C
Interventions
Armodafinil, Sugar Pill
Drug
Lead sponsor
Research Foundation for Mental Hygiene, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Jun 7, 2026, 6:14 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain Injury

NCT00893789
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Armodafinil, Placebo
Drug · Other
Lead sponsor
Cephalon, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
68
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory Performance

NCT00711516
View directory record Official record
Conditions
Excessive Sleepiness
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
9
States / cities
Burlingame, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Armodafinil on Simulated Driving

NCT02468856
View directory record Official record
Conditions
Healthy Volunteers
Interventions
armodafinil, Placebo (for armodafinil)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 35 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Jun 7, 2026, 6:14 AM EDT
Recruiting No phase listed Observational

WAKIX® (Pitolisant) Pregnancy Registry

NCT05536011
View directory record Official record
Conditions
Pregnancy Related, Narcolepsy
Interventions
Pitolisant, Comparator Products
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
Female only
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Jun 7, 2026, 6:14 AM EDT
Terminated Phase 2 Interventional Results available

Nuvigil or Placebo in Newly Diagnosed Malignant Glioma

NCT01400958
View directory record Official record
Conditions
Malignant Glioma
Interventions
Nuvigil®, Placebo
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 15, 2013 · Synced Jun 7, 2026, 6:14 AM EDT
Completed Phase 3 Interventional Results available

Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder

NCT00078312
View directory record Official record
Conditions
Narcolepsy, Sleep Apnea, Obstructive, Sleep Apnea Syndromes, Shift-Work Sleep Disorder
Interventions
CEP-10953 (Armodafinil)
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
41
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Jun 7, 2026, 6:14 AM EDT